Arthramid Vet stands as a groundbreaking solution for addressing non-infectious causes of joint lameness in animals, encompassing both early and late stages of osteoarthritis (OA). This injectable polyacrylamide hydrogel is specifically formulated for intra-articular use, offering a biocompatible and non-absorbable treatment option for joint-related ailments.
The gel’s unique properties facilitate progressive integration into the synovial lining and surrounding tissue of the inner joint capsule. Through a process involving cell migration and vessel ingrowth, Arthramid Vet forms a resilient and cushion-like membrane over a span of 14 to 28 days. This membrane, consisting of vessel-integrated gel covered by new and hypercellular tissue, contributes to enhanced joint stability and function.
Clinical studies have demonstrated that tissue integration and augmentation of the joint capsule typically occur within 2 to 4 weeks post-treatment. However, noticeable improvements in lameness and mobility may manifest earlier in some cases, underscoring the efficacy of Arthramid Vet in promoting joint health and mobility.
Arthrosamid, a related polyacrylamide hydrogel with a 2.5% concentration, has been developed for long-acting intra-articular injections in humans, following the success of Arthramid Vet in equine lameness treatment.
Reviews
There are no reviews yet.